Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy

Patent metadata

Field	Value
Publication number	US-12590331-B2
Application number	US-202117905899-A
Country	US
Kind code	B2
Filing date	Mar 10, 2021
Priority date	Mar 11, 2020
Publication date	Mar 31, 2026
Grant date	Mar 31, 2026

Abstract

Central Serous chorioretinopathy (CSCR) is primarily an ocular disease, affecting the choroid and the retinal pigment epithelium. To date, no systemic biomarker of CSCR have been discovered that could link both forms and help the diagnosis in challenging cases. In the present invention, the inventors measure in European cohorts of CSCR patients (n=168) with (n=90) or without epitheliopathy (n=78) and a cohort of 153 control subjects without any ocular disease history, the serum levels of NGAL and the NGAL/MMP9 complex. Serum NGAL (ng/ml) was significantly higher in the control group (108.8±46.8) than in the CSCR cohort (80.4±46.4, p<0.0001). Serum NGAL (ng/ml) was significantly lower in the acute/recurrent cohort (n=78, 71.3±32.1) than in the control and, than in the chronic cohort (n=90, 88.3±55, p=0.03). Similarly, Serum NGAL/MMP9 (ng/ml) levels was lower in the whole CSCR cohort (44.5±39.6) as compared to the controls (77.6±47.8, p<0.0001). Serum NGAL/MMP9 (ng/ml) were significantly lower in the acute/recurrent cohort (37.6±37.9) than in the control and, than in the chronic cohort (50.5±40.3, p=0.002). Thus, in both forms of CSCR serum NGAL and NGAL/MMP9 are lower than in the control population, providing a biological link between the two forms and a potential susceptibility to oxidative stress and innate immune dysregulation. Systemic LCN2 being elevated in other retinal diseases, it represents a specific biomarker for CSCR.

First claim

The invention claimed is:

1 . A method of determining that a subject has or is at risk of having a central serous chorioretinopathy (CSCR) and treating the subject, comprising
i) measuring a level of neutrophil gelatinase-associated lipocalin (NGAL) in a sample selected from the group consisting of blood, plasma and serum obtained from the subject, wherein the subject is a human; ii) determining the level of NGAL is lower than a predetermined reference value, wherein a difference between the level of NGAL and the predetermined reference value is statistically significant with a p value of 0.03 or less, wherein the predetermined reference value is the level of NGAL determined in samples obtained from a population of healthy individuals, and wherein the difference indicates that the subject has or is at risk of having CSCR; and iii) administering a treatment for CSCR to the subject, wherein the treatment is a drug or therapy selected from the group consisting of anti-VEGF agents, carbonic anhydrase inhibitors, mineralocorticoid (MR) antagonists, laser photocoagulation, diode micropulse laser, verteporfin photodynamic therapy (PDT) and transpupillary thermotherapy.

2 . The method of claim 1 wherein the sample is a serum sample.

3 . A method of predicting the risk of relapse of CSCR in a subject previously treated for CSCR and treating the subject, comprising
measuring the level of neutrophil gelatinase-associated lipocalin (NGAL) in a blood sample obtained from the subject, wherein the subject is a human; determining that the level of NGAL is lower than a predetermined reference value for NGAL measured in blood samples from a population of healthy individuals, wherein the difference between the level of NGAL is statistically significant with a p value of 0.03 or less, indicating that the subject has or is at risk of having a relapse of CSCR; and administering a treatment for CSCR to the subject determined to have the lower level of NGAL, wherein the treatment is a drug or therapy selected from the group consisting of anti-VEGF agents, carbonic anhydrase inhibitors, mineralocorticoid (MR) antagonists, laser photocoagulation, diode micropulse laser, verteporfin photodynamic therapy (PDT) and transpupillary thermotherapy.

4 . The method of claim 1 wherein the treatment is an MR antagonist that is spironolactone or eplerenone.

5 . The method of claim 3 wherein the sample is a serum sample.

6 . The method of claim 1 , wherein the statistically significantly lower level for the subject is at least 18% lower.

7 . The method of claim 3 , wherein the statistically significantly lower level for the subject is at least 18% lower.

Assignees

• Inst Nat Sante Rech Med
• Univ Sorbonne
• Univ Paris Cite
• Hopitaux Paris Assist Publique
• Fond Asile Des Aveugles
• Assist Publique Hopitaux Paris Aphp

Inventors

• Behar-Cohen Francine
• Zhao Min

Classifications

• C12Q2600/158

  Expression markers · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• A61K31/585

  containing lactone rings, e.g. oxandrolone, bufalin · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title